Hofseth BioCare, in collaboration with it's partner Recon Oil, is pleased to announce the grant of its Canadian Patent #2,743,434 covering the use of marine oils in reducing the unique circulatory biomarker, oxLDL-GP, for improved CardioVascular Health.
This is important in the long-term strategy on differentiating our fresh Salmon oil products from conventional Omega 3-products to human and pet health.
Both Hofseth BioCare and Recon are continuing to pursue this patent application in other major jurisdictions globally.
For more information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Mob.: +47 93632966
Email: joo@h-bc.no
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Mob.: +47 93632966
Email: joo@h-bc.no
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.